Ian E. Krop, MD, PhD, on Pictilisib in Metastatic Breast Cancer

2014 San Antonio Breast Cancer Symposium

Ian E. Krop, MD, PhD, of Dana-Farber Cancer Institute, discusses abstract S2-02, “The FERGI phase II study of the PI3K inhibitor pictilisib (GDC-0941) plus fulvestrant vs fulvestrant plus placebo in patients with estrogen receptor–positive, aromatase inhibitor–resistant advanced or metastatic breast cancer: Part I results.”

William J. Gradishar, MD, and Edith A. Perez, MD, on Immunotherapy and highlights of the Bolero-1 and SOFT Trials

William J. Gradishar, MD, of Northwestern University, and Edith A. Perez of the Mayo Clinic Cancer Center, discuss immunotherapy and the highlights of the BOLERO-1...

Breast Cancer

William M. Sikov, MD

William M. Sikov, MD, on the CALGB 40603 Trial

William M. Sikov, MD, of Women and Infants Hospital, discusses abstract S4-05, ...

Breast Cancer

Lisa A. Carey, MD

Lisa A. Carey, MD, on the TNT Trial

Lisa A. Carey, MD, of the UNC Lineberger Comprehensive Cancer Center, discusses abstract S3-01,

Breast Cancer

Edith A. Perez, MD

Edith A. Perez, MD, on Stromal Tumor-Infiltrating Lymphocytes in Early-Stage HER2-Positive Breast Cancer

Edith A. Perez, MD, of the Mayo Clinic Cancer Center, discusses abstract S1-06,

Breast Cancer

Clifford A. Hudis, MD, FACP

Clifford A. Hudis, MD, FACP, on Enzalutamide in Androgen Receptor–Positive, Triple-Negative Breast Cancer

Clifford A. Hudis, MD, FACP, of Memorial Sloan Kettering Cancer Center, discusses findings from abstract P5-19-09, “

May

Today In Oncology

Lisa A. Carey, MD, on the TNT Trial

Edith A. Perez, MD, on Stromal Tumor-Infiltrating Lymphocytes in Early-Stage HER2-Positive Breast Cancer

Clifford A. Hudis, MD, FACP, on Enzalutamide in Androgen Receptor–Positive, Triple-Negative Breast Cancer

Phase II Study of Trilaciclib in Pretreated Patients With Metastatic NSCLC Initiated PRESERVE 4

Safety of Stereotactic Body Radiotherapy for Treatment of Patients With Multiple Metastases

FDA ODAC Votes in Favor of Retaining Accelerated Approval for Bladder Cancer Treatments

Expert Panel–Endorsed Quality Measures for End-of-Life Care for Children With Cancer

One vs Two Doses of the BNT162b2 COVID-19 Vaccine in Patients With Cancer: Immunogenicity and Efficacy

Ian E. Krop, MD, PhD, on Pictilisib in Metastatic Breast Cancer

Related Videos

William J. Gradishar, MD, and Edith A. Perez, MD, on Immunotherapy and highlights of the Bolero-1 and SOFT Trials

William M. Sikov, MD, on the CALGB 40603 Trial